Ultimate magazine theme for WordPress.
BTC
$7,998.39
+1%
ETH
$174.83
+2.36%
LTC
$53.47
+1.35%
DASH
$68.51
+1.35%
XMR
$55.12
-4.59%
NXT
$0.01
0%
ETC
$4.47
+1.52%
DOGE
$0.00
-0.53%
ZEC
$36.80
+1.49%
BTS
$0.03
0%
DGB
$0.01
+0.14%
XRP
$0.30
+3.77%
BTCD
$20.09
PPC
$0.25
-3.25%
CRAIG
$0.00
XBS
$0.02
0%
XPY
$0.04
0%
PRC
$0.01
0%
YBC
$22.40
0%
DANK
$0.00

Bristol-Myers Squibb Co. to Collaborate With FameWave for Non-Small Cell Lung Cancer Study

461

FameWave Ltd., a privately held group developing CM-24, which is being acquired by Kitov Pharma Ltd. (KTOV), disclosed early Friday a clinical collaboration with Bristol Myers Squibb Company (BMY), pushing shares of Kitov by more than 18% in the pre-market.

Shares of Bristol Myers were up 0.7% in the pre-market.

The collaboration is to evaluate the combination of CM-24, FameWave’s monoclonal antibody targeting the novel immune checkpoint carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), with nivolumab (Opdivo), a PD-1 inhibitor, in patients with non-small cell lung cancer (NSCLC).

FameWave and Bristol Myers Squibb will coordinate on the protocol design for the phase 1/2 clinical trial. Under the terms of the deal, FameWave will fund and sponsor the study and Bristol Myers Squibb will supply nivolumab.

The “collaboration is a crucial step to begin evaluation of CM-24 in combination with a PD-1 inhibitor,” said Michael Schickler, CEO of FameWave. “We look forward to evaluating CM-24 in NSCLC since we believe it has a great potential as a novel immune checkpoint to be used in combination therapies for a variety of hard-to-treat cancers.”

Comments